Stifel Financial Corp Decreases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Stifel Financial Corp lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 9.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,593 shares of the medical research company's stock after selling 10,325 shares during the period. Stifel Financial Corp owned approximately 0.20% of Charles River Laboratories International worth $19,814,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in CRL. CWM LLC lifted its position in Charles River Laboratories International by 29.6% in the 2nd quarter. CWM LLC now owns 2,085 shares of the medical research company's stock worth $431,000 after buying an additional 476 shares during the last quarter. Czech National Bank boosted its stake in shares of Charles River Laboratories International by 8.8% in the 2nd quarter. Czech National Bank now owns 9,816 shares of the medical research company's stock valued at $2,028,000 after purchasing an additional 791 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Charles River Laboratories International by 4.9% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 14,216 shares of the medical research company's stock valued at $2,937,000 after purchasing an additional 665 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Charles River Laboratories International by 33.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,114 shares of the medical research company's stock valued at $1,263,000 after purchasing an additional 1,535 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its stake in Charles River Laboratories International by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 9,706 shares of the medical research company's stock worth $2,005,000 after purchasing an additional 75 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Citigroup cut Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their price objective for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. TD Cowen lifted their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. Redburn Atlantic started coverage on Charles River Laboratories International in a research report on Monday, October 14th. They issued a "sell" rating and a $151.00 price objective for the company. Robert W. Baird cut their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a "neutral" rating on the stock in a report on Friday, September 20th. Finally, CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a report on Monday, November 18th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $214.38.

Charles River Laboratories International Stock Down 2.3 %

NYSE:CRL traded down $4.70 during mid-day trading on Tuesday, hitting $197.05. 414,395 shares of the company's stock were exchanged, compared to its average volume of 617,798. Charles River Laboratories International, Inc. has a one year low of $176.48 and a one year high of $275.00. The business has a fifty day moving average price of $194.19 and a 200 day moving average price of $203.56. The company has a market cap of $10.08 billion, a PE ratio of 25.25, a P/E/G ratio of 4.95 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. Charles River Laboratories International's quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.72 EPS. Equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).